Diagnostic Performance and Safety of 18 F-rhPSMA-7.3 PET in Men with Suspected Prostate Cancer Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).

Ashesh B Jani,Gregory C Ravizzini,Benjamin A Gartrell,Barry A Siegel,Przemyslaw Twardowski,Daniel Saltzstein,Mark T Fleming,Albert Chau,Phillip Davis,Brian F Chapin,David M Schuster

The Journal of urology（2023）

引用 0|浏览6

暂无评分

摘要

F-rhPSMA-7.3 offers a clinically meaningful VDR for localization of recurrent prostate cancer. Despite missing the co-primary endpoint of crPPV, the totality of the data support the potential clinical utility of F-rhPSMA-7.3.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要